Good morning, healthcare professional.
Biosimilar adoption accelerates as blockbuster biologic patents expire and payers implement aggressive formulary strategies favoring lower-cost alternatives. Adalimumab biosimilars now capture over 45% of total market volume, while oncology and immunology entrants gain rapid formulary placement.
For community and specialty pharmacies, this shift fundamentally changes how biologic medications are dispensed, managed, and reimbursed. Understanding market dynamics, preparing for therapeutic interchange conversations, and building operational capabilities are now essential competencies.
In today's healthcare digest:
- Biosimilar adalimumab market share reaches 45% milestone
- Fourth adalimumab biosimilar launches with aggressive pricing
- Oncology biosimilar pipeline promises major cost savings
- Payer formulary strategies increasingly favor biosimilar-first policies
Adalimumab Biosimilar Market Share Hits 45%: Faster Than Expected
Bottom Line: Adalimumab biosimilar adoption exceeds forecasts, driven by payer mandates and price competition. Specialty pharmacies must stock multiple biosimilar options, manage patient transitions, and counsel confidently on safety and efficacy equivalence.
Fourth Adalimumab Biosimilar Launches with 85% Discount to Original List Price
Bottom Line: A fourth adalimumab biosimilar launched at 85% below Humira's original list price, intensifying competition. Consolidate biosimilar purchasing through preferred relationships that maximize margin while offering patients competitive pricing.
Oncology Biosimilar Pipeline: Major Cost Savings Ahead
Bottom Line: Biosimilars for bevacizumab, trastuzumab, rituximab, and pembrolizumab (expected 2028) will reshape oncology drug economics. Hospital and specialty pharmacies should build substitution protocols, train staff on clinical data, and engage oncologists to support evidence-based adoption.
Payers Shift to Biosimilar-First Formulary Strategies
Bottom Line: Major commercial payers and Medicare Part D plans increasingly implement biosimilar-preferred or biosimilar-mandatory formulary positions. Update formulary management processes, prepare for increased therapeutic interchange activity, and ensure dispensing systems support efficient substitution workflows.
The Shortlist
- Amgen reported its biosimilar portfolio generated $3.2 billion in 2025 revenue, a 35% increase from 2024.
- The FDA clarified its interchangeability designation pathway, reducing clinical study requirements for certain biosimilar candidates.
- Pharmacy benefit managers increasingly use biosimilar adoption rates as a pharmacy network performance metric.
- Patient acceptance of biosimilars reached 78% in a new survey, up from 62% two years ago.
- European biosimilar markets where adoption exceeds 80% show sustained safety profiles after a decade of use.